This is a working overview of GHRH receptor, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2025-08-02 and is reviewed periodically as new material appears.
Pharmacodynamic studies show that tesamorelin reduces visceral adipose tissue more than subcutaneous adipose tissue in the studied population. This selectivity may relate to differences in blood flow and hormone sensitivity between fat depots. Effects on glucose metabolism and insulin sensitivity have been investigated, with some trials reporting modest changes and others showing stability. The precise relationship between growth hormone exposure, IGF-1 levels, and visceral fat loss remains an active area of analysis.
Tesamorelin binds to growth hormone-releasing hormone receptors on somatotroph cells in the anterior pituitary. Receptor activation increases intracellular cyclic AMP and promotes synthesis and secretion of growth hormone. Because the peptide mimics endogenous GHRH, it amplifies the normal pulsatile release of growth hormone rather than providing exogenous growth hormone directly. This upstream action distinguishes tesamorelin from recombinant growth hormone preparations and from growth hormone secretagogues that act at different receptors.
Stimulated growth hormone release leads to hepatic production of insulin-like growth factor 1, a key mediator of many growth hormone effects. In clinical studies, tesamorelin increased IGF-1 levels in a dose-dependent manner, although the response varies among individuals. The drug's effect on visceral fat is thought to involve growth hormone-mediated lipolysis and altered adipocyte metabolism. Muscle mass and lean body mass have also been assessed as secondary outcomes, but changes are generally smaller and less consistent than fat reductions.
Studies of the compound rely on imaging and laboratory endpoints rather than on symptoms alone. Visceral adipose tissue is usually quantified by computed tomography or magnetic resonance imaging at the level of the abdomen, with waist circumference serving as a cheaper but less specific proxy. Blood work tracks insulin-like growth factor 1, fasting glucose, glycated hemoglobin, and lipid fractions. In the pivotal trials the imaging endpoint fell by roughly fifteen to twenty percent over six months, subcutaneous fat changed little, and the visceral fat returned toward baseline after treatment stopped, a pattern that shapes how clinicians discuss durability.
Whether the drug improves hard clinical outcomes is not settled. No completed trial has shown a reduction in heart attacks or strokes among treated patients, although a dedicated cardiovascular outcomes study has been discussed in the literature. Investigators have also examined hepatic fat in people with HIV and fatty liver disease, cognitive measures in small cohorts, and changes in bone density. Regulatory labeling emphasizes monitoring of insulin-like growth factor 1 because supraphysiologic levels raise questions about tissue growth, and the clinical significance of that signal remains an open question rather than a demonstrated harm.
| Property | Value | Notes |
|---|---|---|
| Primary target | Growth hormone-releasing hormone receptor | Located on anterior pituitary somatotroph cells. |
| Receptor class | G protein-coupled receptor | Activation increases intracellular cyclic AMP. |
| Main downstream hormone | Growth hormone and insulin-like growth factor 1 | Growth hormone release precedes IGF-1 elevation. |
| Primary studied effect | Reduction in visceral adipose tissue | Measured by computed tomography in clinical trials. |
| Approximate half-life | 26–38 minutes after subcutaneous administration | Values vary by assay and study population. |
Tesamorelin acts on the growth hormone-releasing hormone receptor, a G-protein-coupled receptor found on somatotroph cells in the anterior pituitary. Binding triggers a rise in intracellular cyclic AMP, which in turn opens ion channels and raises calcium concentrations, leading to release of stored growth hormone into the bloodstream. Because the peptide works through the same receptor as the body's own GHRH, the resulting secretion follows a pulsatile pattern rather than a continuous elevation. The N-terminal modification slows enzymatic breakdown, so the signal persists longer than it would with the unmodified hormone.
Growth hormone released from the pituitary stimulates the liver and other tissues to produce insulin-like growth factor 1, a stable circulating protein that serves as a practical marker of activity. Clinical studies therefore track IGF-1 concentrations alongside the hormone itself, and they commonly measure body composition with imaging rather than relying on body weight alone. Visceral adipose tissue, the fat surrounding abdominal organs, is quantified by computed tomography in the studies that supported approval. Adverse effects reported in trials include injection-site reactions, joint pain, and increases in blood glucose, which is why monitoring accompanies use.
Once reconstituted, the peptide is handled as a solution and is less stable than the lyophilized powder. Aqueous solutions are commonly kept cold and used within a defined period. Buffer composition and pH influence degradation rates, with extremes of acidity or alkalinity accelerating hydrolysis. Preservatives may be added in multi-dose formats to limit microbial growth. Freezing and thawing of solutions is generally avoided because it can cause precipitation or loss of activity.
Identity and purity are assessed by reversed-phase high-performance liquid chromatography, which separates the peptide from related impurities. Mass spectrometry, often coupled to liquid chromatography, confirms molecular mass and detects chemical modifications. Peptide mapping and amino acid analysis can verify sequence integrity. Water content is measured by Karl Fischer titration, and residual solvents may be checked by gas chromatography. These methods together support batch-to-batch consistency and routine quality control.
Lyophilized tesamorelin is generally stored refrigerated at temperatures between 2 and 8 degrees Celsius. The solid form is comparatively stable when kept dry and protected from light. Moisture uptake can promote aggregation and degradation, so sealed containers with desiccant are common. Researchers typically avoid repeated temperature cycling, which may stress the peptide. Documentation accompanying reference materials usually specifies a shelf life under these conditions.
=== EC 1.14.21 With NADH or NADPH as one donor, and the other dehydrogenated === EC 1.14.21.1: Now EC 1.14.19.64, (S)-stylopine synthase EC 1.14.21.2: Now EC 1.14.19.65, (S)-cheilanthifoline synthase EC 1.14.21.3: Now EC 1.14.19.66, berbamunine synthase EC 1.14.21.4: Now EC 1.14.19.67, salutaridine synthase EC 1.14.21.5: Now EC 1.14.19.68, (S)-canadine synthase EC 1.14.21.6: Now EC 1.14.19.20, Δ7-sterol 5(6)-desaturase EC 1.14.21.7: Now EC 1.14.19.69, biflaviolin synthase EC 1.14.21.8: Now EC 1.14.19.63, pseudobaptigenin synthase EC 1.14.21.9: Now EC 1.14.19.70, mycocyclosin synthase * EC 1.14.21.10: Now EC 1.14.19.71, fumitremorgin C synthase * EC 1.14.21.11: Now EC 1.14.19.72, (–)-pluviatolide synthase * EC 1.14.21.12: Now EC 1.14.19.73, (S)-nandinine synthase *
== Characteristics == The average size of the orifice is 0.3 to 0.4 mm in diameter. There can be two or more foramina separated by a portion of dentin and cementum or by cementum only. If more than one foramen is present on each root, the largest one is designated as the apical foramen and the rest are considered accessory foramina.
Instead, the ionic current from an action potential at one node of Ranvier provokes another action potential at the next node; this apparent "hopping" of the action potential from node to node is known as saltatory conduction. Although the mechanism of saltatory conduction was suggested in 1925 by Ralph Lillie, the first experimental evidence for saltatory conduction came from Ichiji Tasaki and Taiji Takeuchi and from Andrew Huxley and Robert Stämpfli. By contrast, in unmyelinated axons, the action potential provokes another in the membrane immediately adjacent, and moves continuously down the axon like a wave.
Xi supports stronger Party leadership, saying "government, the military, society and schools, north, south, east and west – the party leads them all." During the 100th anniversary of the CCP in 2021, he said that "without the Communist Party of China, there would be no new China and no national rejuvenation," and that "the leadership of the Party is the defining feature of socialism with Chinese characteristics and constitutes the greatest strength of this system." Xi has said that China, despite many setbacks, has achieved great progress under the CCP, saying that "socialism with Chinese characteristics has become the standard-bearer of 21st-century socialist development." However, he also warned that it will take a long time for China under the CCP to complete its rejuvenation, and during this timeframe, party members must be vigilant to not let CCP rule collapse. For the CCP to maintain "purity" and "eternal youth" and not led Party rule to collapse, Xi has called on cadres to engage in self-revolution, through which the CCP roots out corruption and ineffectual officials. Xi has said that "our party is so large, and our country, so huge–it is such that if the Party Central lacks the sole authority to make decisions, nothing can be achieved", comparing the Party Central to the CCP's "cerebrum" and the "central nervous system", and said it "should have the sole authority in making decisions". Xi has spoken out against "historical nihilism", meaning historical viewpoints that challenge the official line of the CCP.
Sources: en.wikipedia.org
=== Cold food chain === Another proposed introduction to humans is through fresh or frozen food products, referred to as the cold food chain. Scientists do not consider this to be a likely origin of SARS-CoV-2 in humans. This scenario's source animal could be either a direct or intermediary species as described above. Many investigations centered around the Huanan Seafood Wholesale Market in Wuhan, which had an early cluster of cases. While there have been food-borne outbreaks of human viruses in the past, and evidence of re-introduction of SARS-CoV-2 into China through imported frozen foods, investigations found no conclusive evidence of viral contamination in products at the Huanan Market.
=== Hygiene and absorbent products === Applications in this field include: super water absorbent material (e.g. for incontinence pads material), nanocellulose used together with super absorbent polymers, nanocellulose in tissue, non-woven products or absorbent structures and as antimicrobial films.
=== Pittsburgh Pirates (1960–62) === Mizell's trade to the Pirates was one of the catalysts of Pittsburgh's championship run that season. Facing the Giants on June 16, 1960, he threw 166 pitches and stayed in the ballgame for three hours and two minutes, allowing two runs through eight innings before allowing three hits to start the ninth and getting charged with three more runs, though he still earned the win in the 10–7 victory. "Shucks, no. I wasn't tired," he quipped after the game. On the strength of two shutouts, he pitched 30 consecutive scoreless innings from July 22 to August 9, the longest such streak of his career. The first shutout may have been his best game of the season; he held the Cubs to two hits in a 4–0 victory on July 29. Six days later, he allowed five hits but no runs to the Giants, securing a 1–0 triumph. On September 18, he won another 1–0 game, limiting Cincinnati to three hits in nine innings. In the month of September, he had a 5–1 record and a 3.14 ERA as the Pirates clinched the NL pennant. Mizell went 13-5 for the Pirates that season (14–8 overall) and finished sixth in the NL in winning percentage (.636). Between St. Louis and Pittsburgh, he had a 3.50 ERA (3.12 with the Pirates), striking out 113 and walking 74 in 211 innings. Of the walks, 10 were intentional. Mizell started Game 3 of the 1960 World Series against the New York Yankees but was removed in the first inning, having given up three hits and a walk while only retiring one hitter. He was charged with the loss as the Yankees won 10–0.
Sources: en.wikipedia.org
Space manufacturing or In-space manufacturing (ISM in short) is the fabrication, assembly or integration of tangible goods beyond Earth's atmosphere (or more generally, outside a planetary atmosphere), involving the transformation of raw or recycled materials into components, products, or infrastructure in space, where the manufacturing process is executed either by humans or automated systems by taking advantage of the unique characteristics of space. Synonyms of Space/In-space manufacturing are In-orbit manufacturing (since most production capabilities are limited to low Earth orbit), Off-Earth manufacturing, Space-based manufacturing, Orbital manufacturing, In-situ manufacturing, In-space fabrication, In-space production, etc. In-space manufacturing is a part of the broader activity of in-space servicing, assembly and manufacturing (ISAM) and is related to in situ resource utilization (ISRU). Three major domains of In-space manufacturing are ISM for space (space-for-space) where products remain in space, ISM for Earth (space-for-Earth) where goods with improved properties produced in outer-space microgravity are transported back to Earth, and ISM for surface where goods are produced on or sent to surfaces of celestial bodies like the Moon, Mars, and asteroids.
== Contraindications == The two contraindications to taking ezetimibe are a previous allergic reaction to it, including symptoms of rash, angioedema, anaphylaxis, and severe liver disease, especially when taken with a statin. Ezetimibe may have significant medication interactions with ciclosporin and with fibrates other than fenofibrate.
==== Pé de Meia ==== On 16 January 2024, Lula sanctioned the Pé de Meia programme, which provides the payment of a monthly financial incentive to high school students, encouraging them to continue studying until completing basic education. The programme aims to contain school evasion or dropouts, which had doubled during the pandemic, and will target students from low-income families registered in CadÚnico, with a per capita family income of up to 218 reais per month. Coming into effect on 26 January 2024, the value of the programme was R$2,000 annually, R$200 upon registration, plus 9 payments of R$200 per school month. In December 2024, the Brazilian Federal Court of Accounts asked for the programme to be blocked after an audit found that the programme was not financially viable.
== Polymorphism == The receptors for oxytocin (OXTR) have genetic differences with varied effects on individual behavior. The polymorphism (rs53576) occurs on the third intron of OXTR in three types: GG, AG, AA. The GG allele is connected with oxytocin levels in humans. A-allele carriers are associated with more sensitivity to stress, lower social proficiency, and more mental health issues than the GG carriers. In a study looking at empathy and stress, individuals with the allele GG scored higher than A-carrier individuals in a "Reading the Mind in the Eyes" test. GG carriers, with their naturally higher levels of oxytocin, were better able to distinguish between emotions. A-allele carriers responded with more stress to stressful situations than GG-allele carriers. A-allele carriers had lower scores on psychological resources, like optimism, mastery, and self-esteem, than GG individuals when measured with factor analysis for depressive symptomology and psychological resources, along with the Beck Depression Inventory. A-allele carriers had higher depressive symptomology and lower psychological resources than GG individuals. A-allele individuals scored lower in human sociality than GG people on a Tridimensional Personality Questionnaire. AA individuals had the lowest amygdala activation while processing emotionally salient information and those with GG had the highest activity when tested using BOLD during an fMRI.
Sources: en.wikipedia.org
It targets the growth hormone-releasing hormone receptor on pituitary somatotroph cells. Binding stimulates cyclic AMP signaling and growth hormone secretion. This is the same receptor used by endogenous GHRH.
It does not act directly on adipose tissue as a primary mechanism. Instead, it increases endogenous growth hormone, which then influences lipolysis and fat distribution. The reduction in visceral fat is an indirect pharmacodynamic effect.
Tesamorelin acts upstream at the pituitary to amplify natural pulsatile growth hormone release. Growth hormone injections provide exogenous hormone and bypass pituitary regulation. The two approaches therefore differ in feedback control and hormonal dynamics.
It mimics a natural hypothalamic signal that tells the pituitary to release growth hormone. The result is a rise in circulating growth hormone and, indirectly, in insulin-like growth factor 1. Over weeks of treatment this shift is associated with a selective decrease in fat stored inside the abdomen.